Letermovir for R+ Study
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Letermovir.
- Who it may be relevant to
- Registry conditions: Kidney Transplant, Liver Transplant. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
An Interventional Study of Letermovir for Primary Prophylaxis of Cytomegalovirus Infection in Moderate Risk (R+) Abdominal Solid Organ Transplant Recipients
Overview
The purpose of this clinical trial is to find out whether a medication, called letermovir, can help prevent a virus called cytomegalovirus (CMV) in participants who receive a kidney or liver transplant and who have already been exposed the CMV. Participants will take letermovir for 84 days.
Detailed description
This study is being done to see if letermovir prevents CMV reactivation in seropositive participants with a kidney or liver transplant.
Interventions
- Drug Letermovir
1 tablet by mouth, once daily, for 84 days
Primary outcome measures
- Efficacy of letermovir as a prophylaxis of CMV [Time frame: 84 days]
Secondary outcome measures (1)
- Percentage of participants who develop cytomegalovirus-specific cell-mediated immunity [Time frame: 84 days]
Eligibility criteria
Inclusion criteria
- Adults who are at moderate risk for CMV after transplant (CMV IGG+, including D+/R+ or D-/R+)
- Adults who received a kidney transplant, liver transplant, or any combination thereof
Exclusion criteria
- Known contraindication to letermovir or its excipients
- Current participation in another CMV related study
- Unwilling or unable to participate in the study protocol
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Prevention
Study locations
United States · 1 center
- University of Wisconsin - Madison — Madison
Identifiers
NCT: NCT07706166 · 2026-0529 · UWMSN | SMPH | Surgery - Trans · Protocol Version 3/12/26